Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?

Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?

Abstract Background Immune checkpoint inhibitors have revolutionized the treatment paradigm of highly lethal malignancies like advanced non-small cell lung cancer (NSCLC), demonstrating long-term tumour control and extended patient survival. Unfortunately, only 25–30% of patients experience a durabl...

Full description

Bibliographic Details
Main Authors: Andrea Botticelli, Bruna Cerbelli, Luana Lionetto, Ilaria Zizzari, Massimiliano Salati, Annalinda Pisano, Mazzuca Federica, Maurizio Simmaco, Marianna Nuti, Paolo Marchetti
Format: Article
Language:English
Published: BMC 2018-08-01
Series:Journal of Translational Medicine
Subjects:
IDO
Immunotherapy
Nivolumab
Kynurenine
Anti-PD-1
Online Access:http://link.springer.com/article/10.1186/s12967-018-1595-3

Internet

http://link.springer.com/article/10.1186/s12967-018-1595-3

Similar Items